According to INC42, Foresite Capital, a healthcare investment firm, has hired Dr. Molly He as a venture partner in their continuous quest of expanding and diversifying their portfolio of transformational firms. Formerly, Dr. He worked as a senior director for a renowned corporation, Illumina. She brings with her a rich experience of 15 years in pharmaceutical and genomic research and development industry. Jim Tananbaum, M.D. and CEO of Foresite Capital, said that Molly is one of the reputable scientific researchers in the field of next-generation sequencing. He added that her expertise and leadership skills will be invaluable to the company. Dr. He studied at Nankai University and the University of California where she graduated with a bachelor’s degree in biochemistry and a PhD in protein physics respectively.
About Jim Tananbaum
Jim Tananbaum is the founder of Foresite Capital. Some of the companies that have benefited from Jim’s expertise are Jazz Pharmaceuticals, Amerigroup, and Amira Pharmaceuticals. Previously, Jim Tananbaum founded Gel Tex Pharmaceuticals where he held several management positions before selling it to Genzyme for $1.6 billion. He serves on the board of directors of Tarsa Therapeutics. He is a proud alumnus of the prestigious Harvard Medical School where he earned his M.D. He holds a B.S.E.E. and a B.S. from Yale University and an MBA from Harvard Business School. Foresite Capital employs the best practices by investing in companies having late-stage innovative products and services in the biotechnology sector, diagnostics, medical devices and healthcare services.
In addition, Jim Tananbaum co-founded Prospect Venture Partners (PVP) in 2001 where he served as a managing director until 2009. PVP was a $1 billion healthcare venture capital group specializing in series A financing. In 1997, he co-founded Theravance (THRX) where he served as the CEO for three years. Previously, he was a partner at Sierra Ventures. At Sierra, he established sound healthcare service investment practice and oversaw investments in Healtheon, Novamed, CareSelect, and Amerigroup. Dr. Jim has a diverse skill set that includes venture capital, biotechnology, start-ups, due diligence and deal sourcing. He is also highly skilled in entrepreneurship, mergers & acquisitions, private equity, IPO and corporate development. Jim serves as the president of the Advisory Board of Yale University. He also sits on the advisory board of Harvard MIT HST Program. More details can be found on Researchgate.
See more: https://www.facebook.com/foresitecapital